We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+98.02%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$340M
Cap. Flow
+$88.1M
Cap. Flow %
7.92%
Top 10 Hldgs %
77.9%
Holding
18
New
1
Increased
3
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$43.7M
2
COGT icon
Cogent Biosciences
COGT
+$32.9M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$15.3M
4
ORKA
Oruka Therapeutics
ORKA
+$4.94M

Top Sells

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.78B
$130M 11.71%
3,307,191
+600,000
+22% +$15.3M
COGT icon
2
Cogent Biosciences
COGT
$6.9B
$129M 11.63%
9,003,418
+2,777,777
+45% +$32.9M
AXSM icon
3
Axsome Therapeutics
AXSM
$12.3B
$99M 8.91%
815,176
– –
APGE icon
4
Apogee Therapeutics
APGE
$10.2B
$81.4M 7.32%
2,048,647
– –
ELVN icon
5
Enliven Therapeutics
ELVN
$3.8B
$76M 6.84%
3,711,444
– –
VRDN icon
6
Viridian Therapeutics
VRDN
$2.2B
$74.7M 6.72%
3,459,913
– –
ORKA
7
Oruka Therapeutics
ORKA
$5.52B
$71.3M 6.41%
3,705,262
+333,340
+10% +$4.94M
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$4.97B
$68.8M 6.19%
1,772,839
– –
SRRK icon
9
Scholar Rock
SRRK
$5.97B
$67.9M 6.11%
1,824,031
– –
SYRE icon
10
Spyre Therapeutics
SYRE
$8.7B
$67.3M 6.06%
4,018,101
– –
NUVL
11
DELISTED
Nuvalent
NUVL
$62.9M 5.66%
727,563
– –
ABVX
12
Abivax
ABVX
$11.1B
$60.6M 5.45%
+713,434
New +$43.7M
ZBIO
13
Zenas BioPharma
ZBIO
$2.06B
$42M 3.78%
1,892,806
– –
JBIO
14
Jade Biosciences
JBIO
$1.24B
$27.8M 2.5%
3,220,368
– –
ATXS
15
DELISTED
Astria Therapeutics
ATXS
$25.9M 2.33%
3,554,129
– –
CBIO
16
Crescent Biopharma
CBIO
$631M
$16.5M 1.48%
1,387,866
– –
IKT icon
17
Inhibikase Therapeutics
IKT
$367M
$9.92M 0.89%
6,125,000
– –
CTMX icon
18
CytomX Therapeutics
CTMX
$725M
– –
-3,896,582
Closed -$8.85M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q3 2025 Portfolio in Review

As of Q3 2025, Fairmount Funds Management held 18 positions worth $1.11B, up 44% from $772M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Fairmount Funds Management deployed $88.1M of net new capital in Q3 2025, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Abivax: 713,434 shares worth $60.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was CytomX Therapeutics, an estimated $8.85M sold.

  • Fairmount Funds Management's largest Q3 2025 buy was Abivax: 713,434 shares worth $60.6M.
  • Fairmount Funds Management added most to Cogent Biosciences in Q3 2025, an estimated $32.9M increase.
  • Fairmount Funds Management fully exited CytomX Therapeutics in Q3 2025, selling an estimated $8.85M.
  • Fairmount Funds Management's ten largest holdings make up 78% of its $1.11B portfolio in Q3 2025.
  • Fairmount Funds Management opened 1 new position and closed 1 in Q3 2025.
  • Fairmount Funds Management's portfolio value rose 44% quarter-over-quarter to $1.11B.

Based on Fairmount Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.